日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial

缩短培洛替酶输注时间治疗接受甲氨蝶呤治疗的未控制痛风患者的安全性、耐受性和疗效：AGILE试验

期刊:Jcr-Journal of Clinical Rheumatology
影响因子:1.8
doi:10.1097/RHU.0000000000002283
Troum, Orrin M; Botson, John K; Fang, Fang; Mohammad, Afroz S; Verma, Supra; LaMoreaux, Brian
痛风
代谢
发表日期：2026
文献求助 收藏

Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase

在培洛替酶的临床试验中，治疗期间出现的主要不良心血管事件和血栓栓塞事件并不常见。

期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/keaf017
Troum, Orrin M; Duong, Mai; Obermeyer, Katie; Padnick-Silver, Lissa; LaMoreaux, Brian
心血管
发表日期：2025
文献求助 收藏

Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis

培洛替酶治疗前未控制痛风的特征和管理：一项为期两年的理赔分析

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-024-00723-9
Morlock, Robert J; Dalal, Deepan; Divino, Victoria; DeKoven, Mitchell; Taylor, Stephanie D; Powers, Atsuko; Barretto, Naina; Holt, Robert J; LaMoreaux, Brian
痛风
代谢
发表日期：2025
文献求助 收藏

Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database

口服降尿酸药物治疗在培洛替酶治疗后的应用及疗效：来自风湿病网络数据库的研究结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00767-5
Padnick-Silver, Lissa; Concoff, Andrew; Gao, Hong-Ye; Fu, Qianhong; LaMoreaux, Brian; Edwards, N Lawrence
发表日期：2025
文献求助 收藏

The Impact of Uncontrolled Gout on Healthcare Utilization and Health Outcomes for United States Veterans Affairs Patients

未控制的痛风对美国退伍军人事务部患者医疗资源利用和健康结果的影响

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00794-2
Vargus, Adriana; Gilmore, Corbyn M; Koeller, Jim M; Lee, Grace C; Patel, Haridarshan; LaMoreaux, Brian; Jones, Xavier F; Frei, Christopher R
痛风
代谢
发表日期：2025
文献求助 收藏

Pegloticase and Methotrexate Cotherapy in Patients With Uncontrolled Gout With Prior Pegloticase Monotherapy Failure: Findings of an Open-Label Trial

培洛替酶联合甲氨蝶呤治疗既往培洛替酶单药治疗失败的难治性痛风患者：一项开放标签试验的结果

期刊:ACR Open Rheumatology
影响因子:2.8
doi:10.1002/acr2.11789
Troum, Orrin M; Botson, John K; Obermeyer, Katie; Chao, Bo; Song, Yang; Zarzoso, Jennifer; Gutierrez, Kjerstina; Verma, Supra; Padnick-Silver, Lissa; LaMoreaux, Brian
代谢
痛风
发表日期：2025
文献求助 收藏

Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis

培洛替酶诱导的强化降尿酸治疗缓解痛风：一项事后临床试验分析

期刊:ACR Open Rheumatology
影响因子:2.8
doi:10.1002/acr2.70080
Klionsky, Yael; Torralba, Karina D; Obermeyer, Katie; Padnick-Silver, Lissa; Lam, Gordon; LaMoreaux, Brian
痛风
代谢
发表日期：2025
文献求助 收藏

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation

停用培洛替酶后痛风患者的降尿酸治疗、血清尿酸、炎症生物标志物和肾功能

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-024-03318-5
Holladay, Emily E; Mudano, Amy S; Xie, Fenglong; Zhang, Jingyi; Mikuls, Ted R; LaMoreaux, Brian; Padnick-Silver, Lissa; Curtis, Jeffrey R
炎症/感染
痛风
炎症
代谢
发表日期：2024
文献求助 收藏

Skeletal muscle mass and quality in gout patients versus non-gout controls: A computed tomography imaging study

痛风患者与非痛风对照组的骨骼肌质量和质量：一项计算机断层扫描成像研究

期刊:Joint Bone Spine
影响因子:4.3
doi:10.1016/j.jbspin.2024.105743
Covello, Allyson; Toprover, Michael; Oh, Cheongeun; Leroy, Gregoire; Kumar, Ada; LaMoreaux, Brian; Mechlin, Michael; Fields, Theodore R; Pillinger, Michael H; Becce, Fabio
痛风
代谢
发表日期：2024
文献求助 收藏

Real-World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy

培洛替酶联合免疫调节疗法在现实世界中的疗效

期刊:Arthritis Care & Research
影响因子:3.3
doi:10.1002/acr.25361
Holladay, Emily E; Mudano, Amy S; Xie, Fenglong; Zhang, Jingyi; Mikuls, Ted R; Saag, Ken; Yun, Huifeng; LaMoreaux, Brian; Francis-Sedlak, Megan; Curtis, Jeffrey R
免疫/内分泌
发表日期：2024
文献求助 收藏